Fusarium solani

30
RaphaelMasson

Content Fusarium solani is a filamentous ubiquitary yeast

References.................................................................. 182 belonging to the family of Fusarium which groups
several species. It is a pathogen of plants touch-
ing immunodepressed patients [1]. The prognosis
is severe [2]. Known risk factors are neutrope-
nia and trauma. Entering ways are the skin (cel-
lulitis), nails (onychomycosis), lungs (sinuses,
lungs), or eyes (keratitis) [3]. Dissemination is
done by blood and induces fever in most of the
cases.
A skin necoritc aspect is observed in immuno-
depressed patients, looking like ecthyma gan-
grenosum disseminated [4].
Bad prognosis factors are persisting neutro-
penia and corticosteroid long-term treatments
[5, 6].
The check-up should include hemoccults and
biopsies of the involved tissues for analysis of
cultures and histopathological samples.
The sensibility to antifungal therapies of
Fusarium solani is demonstrated by CMI >8 to
itraconazole, voriconazole, and posaconazole.
CMI 50 and CMI 90 for amphotericin B are,
respectively, at 1 and 4 which makes amphoteri-
cin B the best activity invitro over this yeast [6].
But CMI is not correlated to efficacy of antifun-
gic agensts and voriconazole may be an option in
the treatment of invasive fusarioses [7].
R. Masson, MD
Infectiologist Wound Healing Unit,
The therapeutic strategy is based on correcting
Montpellier University Hospital, Montpellier, France the risk factors, a surgical debridement associ-
e-mail: r-masson@chu-montpellier.fr ated to an antifungic treatment.

L. Tot et al. (eds.), Skin Necrosis, 181

DOI 10.1007/978-3-7091-1241-0_30, Springer-Verlag Wien 2015
182 R. Masson

References 5. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA,

Trabasso P, Solza C, etal. Outcome predictors of 84
patients with hematologic malignancies and Fusarium
1. Venditti M, Micozzi A, Gentile G, Polonelli L,
infection. Cancer. 2003;98(2):3159.
Morace G, Bianco P, etal. Invasive Fusarium solani
6. Cuenca-Estrella M, Gomez-Lopez A, Mellado E,
infections in patients with acute leukemia. Rev Infect
Buitrago MJ, Monzon A, Rodriguez-Tudela JL.Head-
Dis. 1988;10(3):65360.
to-head comparison of the activities of currently avail-
2. Rabodonirina M, Piens MA, Monier MF, Guho E,
able antifungal agents against 3,378 Spanish clinical
Fire D, Mojon M.Fusarium infections in immu-
isolates of yeasts and filamentous fungi. Antimicrob
nocompromised patients: case reports and lit-
Agents Chemother. 2006;50(3):91721.
erature review. Eur J Clin Microbiol Infect Dis.
7. Lortholary O, Obenga G, Biswas P, Caillot D,
1994;13(2):15261.
Chachaty E, Bienvenu A-L, etal. International ret-
3. Chang DC, Grant GB, ODonnell K, Wannemuehler
rospective analysis of 73 cases of invasive fusa-
KA, Noble-Wang J, Rao CY, etal. Multistate outbreak
riosis treated with voriconazole. Antimicrob Agents
of Fusarium keratitis associated with use of a contact
Chemother. 2010;54(10):444650.
lens solution. JAMA. 2006;296(8):95363.
4. Repiso T, Garca-Patos V, Martin N, Creus M, Bastida
P, Castells A.Disseminated fusariosis. Pediatr
Dermatol. 1996;13(2):11821.